AnPac Bio-Medical Science Profit Margin 2020-2021 | ANPC

Current and historical gross margin, operating margin and net profit margin for AnPac Bio-Medical Science (ANPC) over the last 10 years. Profit margin can be defined as the percentage of revenue that a company retains as income after the deduction of expenses. AnPac Bio-Medical Science net profit margin as of June 30, 2021 is 0%.
AnPac Bio-Medical Science Annual Profit Margins
AnPac Bio-Medical Science Quarterly Profit Margins
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.026B $0.003B
AnPac Bio-Medical Science Co., Ltd. is a biotechnology company focused on early cancer screening and detection. AnPac Bio-Medical Science Co., Ltd. is based in China.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $121.281B 7.66
Bio-Rad Laboratories (BIO.B) United States $22.443B 45.55
QIAGEN (QGEN) Netherlands $12.681B 21.48
Biohaven Pharmaceutical Holding (BHVN) United States $7.357B 0.00
Arcus Biosciences (RCUS) United States $3.170B 0.00
Emergent Biosolutions (EBS) United States $2.265B 8.14
Myovant Sciences (MYOV) United Kingdom $1.741B 0.00
ADC Therapeutics SA (ADCT) Switzerland $1.500B 0.00
Zymeworks (ZYME) Canada $0.902B 0.00
Ambrx Biopharma (AMAM) United States $0.391B 0.00
SQZ Biotechnologies (SQZ) United States $0.337B 0.00
Enzo Biochem (ENZ) United States $0.162B 15.95